Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Phase 2 Recruiting 55 enrolled Alain Algazi American Head and Neck Society · collab Genentech, Inc. · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.

Timeline

Start: 2019-03-08
Primary completion: 2028-06-30
Completion: 2028-06-30

Publications

Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, Tamaki SJ, Marquez DM, Tenvooren I, Wai K, Cheung A, Davidson BR, Johri V, Samad B, O'Gorman WE, Krummel MF, van Zante A, Combes AJ, Angelo M, Fong L, Algazi AP, Ha P, Spitzer MH. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023 Mar 16;186(6):1127-1143.e18. doi: 10.1016/j.cell.2023.02.021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atezolizumab	Monoclonal antibody	840 mg	Intravenous
Subject	Atezolizumab	Monoclonal antibody	1200 mg	Intravenous
Subject	Tiragolumab	Monoclonal antibody	600 mg	Intravenous
Subject	Tocilizumab	Monoclonal antibody	6 mg/kg	Intravenous

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Summary

Timeline

Publications

Drugs

Indications